Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 12/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.55 |
| ▸ | ATG7 | O95352 | 1/20 | 0.55 |
| ▸ | UBA7 | P41226 | 1/20 | 0.55 |
| ▸ | NAE1 | Q13564 | 1/20 | 0.55 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.55 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12566425 | 0.91 | DNPH1 (0.62) | DNPH1CA1CA2CA4CA9 | |
| SCHEMBL12566847 | 0.91 | DNPH1 (0.62) | DNPH1CA1CA2CA4CA9 | |
| SCHEMBL1796907 | 0.91 | DNPH1 (0.73) | DNPH1CA1CA2CA4CA9 | |
| SCHEMBL12566850 | 0.89 | DNPH1 (0.76) | DNPH1CA1CA2CA4CA9 | |
| SCHEMBL12566848 | 0.89 | DNPH1 (0.61) | DNPH1CA1CA2CA4CA9 | |
| SCHEMBL12567223 | 0.85 | CA1 (0.56) | DNPH1CA1CA2CA4CA9 | |
| SCHEMBL12652511 | 0.84 | DNPH1 (0.63) | DNPH1CA1CA2CA4CA9 | |
| SCHEMBL1798212 | 0.84 | CA1 (0.53) | CA1CA2CA4CA9UBA6 | |
| SCHEMBL1797355 | 0.83 | UBA6 (0.57) | DNPH1CA1CA2CA4CA9 | |
| SCHEMBL1797794 | 0.83 | UBA6 (0.59) | UBA6ATG7UBA7NAE1UBA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7951810-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | DNPH1 336/4885CA1 2434/4885CA2 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.